The pneumococcal (Pn) conjugate vaccine includes seven different polysaccharides (PS) conjugated to CRM 197 . Utilizing antigen-processing cells and a CRM 197 -specific mouse T-cell hybridoma, we found that the serotype of conjugated PnPS dramatically affected antigen processing of CRM 197 . Unconjugated CRM 197 and serotype conjugates 14 and 18C were processed more efficiently.
Antibodies (Ab) against capsular polysaccharides (PS) of
Streptococcus pneumoniae (Pn) are protective against disease in animal models and in humans (15, 21) . PS antigens, however, are T-independent type 2 antigens and generally do not induce immunological memory or a protective Ab response in infants less than 24 months of age (3, 5, 12, 15, 20, 21) .
Immunization with PS conjugated to a carrier protein results in induction of protective levels of anti-PS Ab in infants as well as immunological memory (2, 21) . The first effective conjugate vaccine used purified Haemophilus influenzae type b (Hib) PS linked to CRM 197 (cross-reactive material), a nontoxic mutant diphtheria toxin (22) , while other Hib vaccines use different carrier proteins. The use of these conjugate vaccines has resulted in the virtual eradication of Hib infections in the United States (2) .
The currently licensed heptavalent PnPS conjugate vaccine is a combination vaccine containing seven purified serotypes of PnPS (4, 6B, 9V, 14, 18C, 19F, and 23F) individually conjugated to CRM 197 . This vaccine targets the Pn serotypes most frequently responsible for pediatric invasive disease in the United States (8, 9) and has been shown to have protective efficacy against invasive disease from homologous serotypes in children after four doses of vaccine (1, 17, 19) .
Despite conjugation to the same carrier protein, the PnPS contained in the heptavalent conjugate vaccine elicit markedly different serotype-specific Ab titers in children and adults (1, 11, 17, 19) . One potential explanation for the serotype-specific variation in immunogenicity of the components of the vaccine is that structurally different PnPS might affect antigen processing of the carrier protein, CRM 197 , yielding differences in carrier protein-induced T-cell help. We studied the effect of the serotype of PnPS conjugated to CRM 197 on antigen processing of the carrier protein in cells from HLA-DR1-transgenic mice.
HLA-DR1-transgenic mice obtained from Merck Research Laboratories had a mixed background (C57BL/6, SJL/J, and B10.M) with a fixed H-2 f locus (18) . The Animal Care and Use Committee of Case Western Reserve University approved all of the animal protocols that were used. These mice were immunized with CRM 197 and complete Freund's adjuvant. Lymph nodes were harvested, the cells were restimulated in vitro with CRM 197 , and restimulated T cells were fused with BW1100 CD4-transfected cells by using polyethylene glycol (16) . Successfully fused cells were selected with hypoxanthineaminopterin-thymidine. The hybridoma cells were screened for responses to CRM 197 and HLA-DR1 restriction by using THP-1 cells, an HLA-DR1-expressing immortalized cell line, and then were cloned by limiting dilution. T-cell responses to antigen-processing cells (APC) presenting CRM 197 peptides were measured as interleukin 2 (IL-2) production via enzymelinked immunosorbent assay (ELISA) as previously described (23) . The precise peptide to which the hybridoma responded was determined by using a series of overlapping peptides from the A and B chains of the CRM 197 protein, adding them to splenocytes from the mice as APC, and measuring T-cell IL-2 production. The greatest response was observed with two adjacent peptides from the B fragment of CRM 197 with the amino acid sequences PGKLDVNKSKTHISVN (CRM 197 residues 245 to 260) and DVNKSKTHISVNGRKI (CRM 197 residues 249 to 264). These peptides thus contain the epitope for this hybridoma (Fig. 1) . No response was observed with peptides from the A fragment of CRM 197 (data not shown).
In order to determine if the serotype of the PnPS affects processing of the carrier protein, multiple lots of PnPS-CRM 197 conjugate types 4, 6B, 9V, 14, 18C, 19F, and 23F (kindly supplied by Ronald Eby, Wyeth Vaccines, West Henrietta, N.Y.) were added to wells containing HLA-DR1-transgenic mouse splenocytes (1 ϫ 10 5 ) or bone marrow macrophages (BMM; 1 ϫ 10 5 ) in medium supplemented with recombinant mouse gamma interferon (R&D Systems, Inc., Minneapolis, Minn.), diluted according to the concentration of CRM 197 (0 to 16 g/ml). Hen egg lysozyme (HEL; Sigma-Aldrich Co., St. Louis, Mo.) was used as a negative control protein, and individual free PS from serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F (American Type Culture Collection, Manassas, Va.) were also used as negative controls. T hybridoma cells (10 5 ) were then added to each well. The degree of peptide-major histocompatibility complex (MHC) presentation to the hybridoma was determined via IL-2 ELISA of the well supernatant after incubation. Splenocyte processing of the conjugates containing different serotypes of PnPS linked to CRM 197 yielded markedly different presentation of the CRM 197 peptide to the T-cell hybridoma ( Fig. 2A) . Unconjugated carrier protein was better recognized by the hybridoma than any of the PnPS-CRM 197 conjugates, while carrier protein from serotype 14 and 18C conjugates was more efficiently processed and presented than that from the 9V, 4, and 23F conjugates. Carrier proteins from the serotype 19F and 6B conjugates were presented least efficiently, with recognition by the hybridoma being only slightly better than that demonstrated by incubation with HEL ( Fig.  2A) . None of the control unconjugated PnPS serotypes elicited IL-2 production, and addition of free PS to CRM 197 did not affect antigen processing (data not shown). Similar results were obtained when BMM from HLA-DR1-transgenic mice were used as APC. As observed in the splenocyte experiments, unconjugated CRM 197 was processed most efficiently, and CRM 197 conjugated to serotypes 14 and 18C was presented more efficiently than that conjugated to serotypes 4 and 6B (Fig. 2B) . Differences in protein content of the individual PnPS serotype-CRM 197 conjugates did not explain the different responses, since the components were diluted to contain identical quantities of CRM 197 (the protein content of the conjugates was confirmed by bicinchoninic acid protein assay). Similar results were also obtained with different lots of vaccine.
The proposed mechanism for the enhanced immunogenicity of PS-protein glycoconjugate vaccines compared to that of pure PS involves recognition and internalization of the glycoconjugate by a PS-specific B cell, endosomal proteolysis of the carrier protein, noncovalent association of peptide fragments with class II MHC molecules, and presentation of this complex at the cell surface to a CD4 ϩ T cell with receptor specificity for the carrier protein and the MHC molecule (4, 6, 23) . The association of carrier-derived, MHC II-bound peptide with the T-cell receptor activates the T cell to secrete a variety of cytokines along with CD40/CD40L interactions that presumably stimulate the PS-specific B cell to proliferate, secrete Ab, undergo isotype switching, and differentiate into memory cells.
PS do not bind to class II MHC molecules and, therefore, do not directly activate T cells (7, 10) . However, Ishioka et al. observed that glycosylation of a known peptide T-cell epitope affected the MHC binding and T-cell recognition of the peptide depending on the location of the carbohydrate moieties relative to the residues of the core MHC-binding regions on the peptide (10). When carbohydrate was located in the core MHC-binding region, either T-cell recognition was abolished or the antigenic determinant recognized by the T cell was altered. It seems probable that the structure of the carbohydrate conjugated to CRM 197 influences the variety of epitopes produced from carrier protein if proteolysis or MHC binding is affected. We also previously demonstrated that T cells from mouse lymph nodes generated by immunization with CRM 197 alone, 6B-CRM 197 , 19F-CRM 197 , or 23F-CRM 197 recognized different peptide epitopes on the carrier protein when screened with the same 16-mer peptides used to map our T-cell hybridoma (14) . This finding again suggests that the serotype of the PS had influence over the T-cell epitopes produced by the APC. Since the linkage sites in the PnPS conjugates between PS and protein are random, individual PnPS serotypes are not conjugated to the same part of the CRM 197 molecule. Thus, the observed differences in the antigen processing of the various conjugates by APC may relate to the proximity of the PS linkage to the MHC-binding region of the carrier protein (10) .
We demonstrated substantial differences in the presentation of CRM 197 to T-hybridoma cells by APC after processing of different serotypes of PnPS-CRM 197 conjugates. Other studies have shown that the individual components of the PnPS conjugate vaccine elicit different patterns of cytokine responses from carrier-specific T cells. Mice immunized with type PnPS vaccines produced markedly different cytokine responses in splenocytes upon restimulation with the conjugates (13) . These cytokine profiles were associated with different immunoglobulin G subclass Ab responses against the PS.
The observed differences in the efficiency of CRM 197 processing based on the serotype of the attached PnPS would not likely explain the variable serotype specific anti-PS Ab responses noted in both mice and humans. Since all seven serotypes of PnPS conjugated to CRM 197 in the multivalent vaccine are administered simultaneously, such differences in efficiency of antigen processing may be irrelevant in immunized humans. In addition, we have recently reported that CD4 ϩ T cells taken (11) . These data suggested that B-cell repertoire, not lack of T-cell help, might also be an important cause of the serotype-specific differences in the immunogenicity of this heptavalent vaccine in adults. Differences in the quality or quantity of T-cell help in infants immunized with conjugate vaccines might be a possible explanation for the differences in isotype-specific response to conjugate vaccine. A limitation of our study was a lack of access to neonatal HLA-DR1-transgenic mice to explore the effect of PS-protein conjugation on the processing of the carrier protein by immature APCs. Future studies with animal and human subjects should be performed with these glycoconjugates to determine if differences in the haplotype of MHC molecules affect antigen processing and, ultimately, immunogenicity. Since T cells from the HLA-DR1-transgenic mouse will respond to APC from HLA-DR1 ϩ humans (approximately 12% of the population), future experiments can also explore the kinetics and character of processing of CRM 197 when conjugated to various PnPS serotypes by human APCs. A similar approach could be used with T-cell hybridomas restricted to other human HLA-DR alleles. 
